“…4,5 In 1998 the U.S. Food and Drug Administration (FDA) approved the use of Cosopt, a combination topical medication, containing 2% dorzolamide and 0.5% timolol. Compared with acetazolamide, dorzolamide has been reported to be more, 6,7 equally, [8][9][10][11] or less effective. 12,13 Topical dorzolamide was better tolerated and produced a significant intraocular pressure reduction in a group of pediatric glaucoma patients.…”